Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Discover how GMP consulting services help pharmaceutical companies strengthen quality management systems, improve validation, enhance FDA inspection readiness, and reduce compliance risks through practical, risk-based strategies that support sustainable regulatory success across the entire product lifecycle.
The FDA has issued a warning letter to Sanofi’s Genzyme manufacturing facility in Waterford, Ireland, after identifying significant weaknesses in Data Integrity and quality management during an inspection. The agency found deficiencies in laboratory record reviews, traceability, and deviation handling
Discover how pharmaceutical companies use ICH Q9 principles, GMP risk assessment, and CAPA integration to strengthen quality oversight, improve inspection readiness, and build effective quality risk management programs that support compliance, patient safety, and continuous improvement in 2026.
This article explains the regulatory relationship between CMC and GMP, highlighting key differences, inspection findings, and compliance expectations. It shows how documentation, validation, and manufacturing control connect to FDA and global pharmaceutical quality system requirements.